STOCK TITAN

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Ocugen, Inc. completes dosing in the second cohort of the Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy in dry age-related macular degeneration. The therapy targets approximately 1 million affected individuals in the US.
Ocugen, Inc. ha completato la somministrazione nel secondo gruppo del trial clinico di Fase 1/2 ArMaDa per OCU410, una terapia genica per l'atrofia geografica nella degenerazione maculare senile secca. La terapia mira a circa 1 milione di individui colpiti negli Stati Uniti.
Ocugen, Inc. ha completado la dosificación en el segundo grupo del ensayo clínico ArMaDa de Fase 1/2 para OCU410, una terapia génica para la atrofia geográfica en la degeneración macular relacionada con la edad seca. La terapia está dirigida a aproximadamente 1 millón de individuos afectados en los EE.UU.
Ocugen, Inc.는 OCU410에 대한 건성 노인성 황반변성 지리적 위축에 대한 유전자 치료제인 1/2단계 ArMaDa 임상 시험의 두 번째 코호트에서 투여를 완료했습니다. 이 치료는 미국에서 약 100만 명의 영향을 받은 개인을 대상으로 합니다.
Ocugen, Inc. a achevé l'administration dans le deuxième groupe de l'essai clinique ArMaDa de Phase 1/2 pour OCU410, une thérapie génique pour l'atrophie géographique dans la dégénérescence maculaire liée à l'âge sèche. La thérapie vise environ 1 million de personnes touchées aux États-Unis.
Ocugen, Inc. hat die Verabreichung in der zweiten Gruppe der Phase-1/2-ArMaDa-Klinischen Studie für OCU410, eine Gentherapie gegen geografische Atrophie bei trockener altersbedingter Makuladegeneration, abgeschlossen. Die Therapie zielt auf ungefähr 1 Million betroffene Personen in den USA ab.
Positive
  • None.
Negative
  • None.

The completion of dosing in the second cohort of Ocugen's ArMaDa clinical trial for OCU410 is a pivotal step in the drug's development pathway. With geographic atrophy affecting a sizable patient population in the U.S., the potential market for an effective treatment could be significant. Investors should monitor the progression of this trial closely, as positive results can lead to increased valuations due to the high unmet medical need in this space. However, the inherent risks of clinical trials, especially in the early phases, should temper expectations as many compounds fail to demonstrate efficacy or safety at later stages.

OCU410 represents a novel approach in the treatment of geographic atrophy, a condition with limited therapeutic options. Modifier gene therapy aims to correct the underlying genetic disruptions that contribute to the disease's progression. The success of such therapies can revolutionize treatment paradigms; however, clinical efficacy and safety profiles remain to be established. For stakeholders, the long-term impact hinges on Phase 3 trial outcomes and regulatory approvals, which are heavily influenced by the robustness of Phase 1/2 trial data.

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States alone.

“We are very enthusiastic about the potential of OCU410 as a one-time, gene-agnostic option for the treatment of GA,” said Dr. Huma Qamar, Chief Medical Officer of Ocugen. “OCU410 regulates multiple pathways involved with the disease, including lipid metabolism, inflammation, oxidative stress, and membrane attack complex (complement) with a single sub-retinal injection.”

Dosing in the second cohort is complete and 3 subjects received 200 mL single subretinal administration of the medium dose (5x1010 vg/mL) of OCU410. Up to 13 leading retinal surgery centers across the United States are participating in the ArMaDa clinical trial.

“Currently we have two FDA approved, anti-complement therapies for GA targeting a single pathway of the disease, which has multifactorial and complex etiology,” said Syed M. Shah, MD, Vice Chair of Research and Digital Medicine and Director of Retina Service at Gundersen Health System, La Crosse, WI, and the lead investigator for the OCU410 Phase 1/2 trial. “The limited benefit comes with the burden of continued multiple intravitreal injections spanning over several years. This novel modifier gene therapy has the potential to transform the therapeutic landscape in GA treatment.”

A Data and Safety Monitoring Board meeting will convene next month to review the 4-week safety data of the medium dose cohort before proceeding with high dose, which is the final dose in the Phase 1 dose-escalation study.

The ArMaDa Phase 1/2 clinical trial will assess the safety of unilateral subretinal administration of OCU410 in subjects with GA and will be conducted in two phases. Phase 1 is a multicenter, open-label, dose-ranging study consisting of three dose levels [low dose (2.5×1010 vg/mL), medium dose (5×1010 vg/mL), and high dose (1.5 ×1011 vg/mL). Phase 2 is a randomized, outcome accessor-blinded, dose-expansion study in which subjects will be randomized in a 1:1:1 ratio to either one of two OCU410 treatment groups or to an untreated control group.

The Company will continue to provide clinical updates on an ongoing basis.

About dAMD and GA
dAMD affects approximately 10 million Americans and more than 266 million people worldwide. It is characterized by the thinning of the macula. The macula is the part of the retina responsible for clear vision in one’s direct line of sight. dAMD involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function and central vision impairment. dAMD accounts for 85-90% of the total AMD population.

About OCU410
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (ROR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role as well as inhibiting the complement system in in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA.

About Ocugen, Inc. 
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact: 
Tiffany Hamilton 
Head of Communications 
Tiffany.Hamilton@ocugen.com  


FAQ

What is the latest update from Ocugen regarding its clinical trial for OCU410?

Ocugen has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy in dry age-related macular degeneration.

What is the target condition for OCU410?

OCU410 is being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration.

How many individuals are affected by geographic atrophy in the US?

Geographic atrophy affects approximately 1 million people in the United States.

What type of therapy is OCU410?

OCU410 is a modifier gene therapy candidate.

Ocugen, Inc.

NASDAQ:OCGN

OCGN Rankings

OCGN Latest News

OCGN Stock Data

450.32M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
United States of America
MALVERN

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.